SCHEMBL3962633

SCHEMBL3962633

O=C(Nc1ccccn1)Nc1cc(Cl)ccc1C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 18/20 1.00
▸ NPC1 O15118 2/20 0.60
▸ RAB9A P51151 2/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ KMT2A Q03164 1/20 0.60
▸ GRIK2 Q13002 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5950391 0.84 GRIK1 (0.72) GRIK1RAB9AMEN1KMT2A
SCHEMBL1462409 0.83 GRIK1 (0.70) GRIK1NPC1RAB9A
SCHEMBL1307746 0.82 GRIK1 (0.70) GRIK1MEN1KMT2A
SCHEMBL3957527 0.80 GRIK1 (1.00) GRIK1GRIK2
SCHEMBL3961520 0.80 GRIK1 (1.00) GRIK1GRIK2
SCHEMBL3961542 0.78 GRIK1 (1.00) GRIK1GRIK2
SCHEMBL1462967 0.77 GRIK1 (1.00) GRIK1GRIK2
SCHEMBL5950252 0.77 GRIK1 (1.00) GRIK1MEN1KMT2AGRIK2
SCHEMBL3961219 0.77 GRIK1 (1.00) GRIK1GRIK2
SCHEMBL6185945 0.77 GRIK1 (0.62) GRIK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2006-03-30 — — US claimed
EP-1565429-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2005-08-24 — — EP claimed
WO-2004046090-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2004-06-03 — — WO claimed
EP-1565429-B1 DIARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH AS (DK) 2009-05-13 — — EP disclosed
US-7521480-B2 Aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2009-04-21 — — US disclosed
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use NEUROSEARCH (DK) 2006-03-30 — — US disclosed
EP-1565429-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2005-08-24 — — EP disclosed
WO-2004046090-A2 ARYL UREIDO DERIVATIVES AND THEIR MEDICAL USE NEUROSEARCH A/S (DK) 2004-06-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069255-A1 Novel aryl ureido benzoic acid derivatives and their use GABRA5, GRIK5, GRM5 GRIK1 24/4885NPC1 2512/4885RAB9A 3763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback